Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Five Pillars Nurses Should Follow in Treating Immune-Related Adverse Events

      August 5, 2019
      By Kristie L. Kahl
      Article
      Conferences|Annual School of Nursing Oncology

      To assist in treating patients with immune-related adverse events (irAEs), nurses can follow 5 pillars: prevent, anticipate, detect, treat, and monitor.

      To assist in treating patients with immune-related adverse events (irAEs), nurses can follow 5 pillars: prevent, anticipate, detect, treat, and monitor.

      “To go through your role, really talking about what framework you can use as nurses in oncology to help manage the toxicity profile that your patients have, I really like the Champlat et al model, which goes through the 5 pillars of management of immunotherapy,” Marianne Davies, DNP, RN, CNS, ACNP-BC, AOCNP, who is an associate professor and oncology nurse practitioner at the Yale Comprehensive Cancer Center, said during a presentation at the 3rd Annual School of Nursing Oncology. “It can help guide your practice.”

      Prevent

      The first part to preventing irAEs is to evaluate patients for autoimmune risks before starting treatment. These can include Addison’s disease, celiac disease, Crohn’s disease, Grave’s disease, Hashimoto’s thyroiditis, multiple sclerosis, myasthenia gravis, pernicious anemia, rheumatoid arthritis, Sjogren’s syndrome, systemic lupus erythematosus, type 1 diabetes, and ulcerative colitis.

      In addition, nurses should be aware of patients who have had any prior organ transplantations or hematopoietic stem cell transplantation for the potential risk of graft rejection.

      Nurses should also be prepared for medication reconciliation, which includes over-the-counter drugs and herb supplements.

      “There are several levels of prevention or preparing patients for treatment,” Davies said. “One of the key ones is that your institution needs to be behind you and provide appropriate resources to help you manage your patients that are on therapy.”

      Anticipate

      The next pillar is how nurses can anticipate irAEs through assessment at baseline, during treatment, and after treatment. Assessments can include a review of systems, physical examinations, and laboratory evaluations for complete blood count, a comprehensive metabolic panel, and a thyroid panel.

      “How do we prevent toxicities for patients, or prepare to be able to best manage those? That is by understanding not only the mechanism of action of the checkpoint inhibitors, but also understanding how we manage each of the specific toxicities,” Davies said, adding that patients also have a responsibility when it comes to anticipating irAEs.

      “Patients need to be encouraged and instructed to report any new symptoms that they do have because even subtle symptoms may be an immune-related toxicity and that is really important for us to understand. The earlier we can manage the toxicity, most often, these patients can successfully go on to continue on that therapy. So, we need to encourage and educate our patients of that.”

      Detect

      Similar to anticipation, both the healthcare providers and the patients play a role in detecting irAEs.

      Healthcare providers should conduct regular monitoring of the patients, using standardized irAE assessment checklists, telephone triages, and toxicity management guidelines. In addition, nurses should be sure to always rule out any other cause of toxicity. Lastly, they should assess and monitor the kinetics of the toxicity after it is treated.

      Following these steps, the healthcare team is then responsible for determining the need for hospitalization or ambulatory care.

      On the other hand, treatment with immunotherapy requires patients to have close communication with their healthcare providers. They should report any new signs or symptoms they develop, as well as if they have been seen by any other healthcare provider or were admitted to the hospital for an irAE.

      Treat

      After detecting irAEs, the next pillar is to actually treat the toxicity. To do so, Davies offered various sources that nurses can utilize for reference, including guidelines from the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), the Society for Immunotherapy of Cancer (SITC), and the AiM with Immunotherapy Foundation.

      Monitor

      Similar to detection, when monitoring irAEs, healthcare providers must monitor the kinetics of the toxicity. In addition, nurses should monitor for resolution of the toxicity, complications of the immune suppressant drugs, and treatment response.

      “Communication is the essential thread,” Davies said, adding that the multidisciplinary team plays a key role in managing irAEs. “Some other key things we can do is helping to identify ‘IO champions’ within your facility that can help be there and be a resource to you as you are going through this.”

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a man in a suit smiling in front of an Oncology Nursing News background
      Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
      Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
      Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
      Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
      Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
      Image of a woman with white hair in front of an Oncology Nursing News blue background
      Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
      Man in suit standing in front of blue watercolor Oncology Nursing News backdrop
      Related Content

      Graphic of kidneys

      Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC

      Kyle Doherty
      July 1st 2025
      Article

      ALLO-316 showed significant activity and safety in patients with metastatic CD70-positive clear cell renal cell carcinoma.


      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Fischer
      April 3rd 2023
      Podcast

      Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.


      Image of icons representing different organs in a circle with the female reproductive system in the middle under a magnifying glass

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      Chris Ryan
      June 23rd 2025
      Article

      The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.


      The Vitals

      Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

      Lindsay Fischer
      March 1st 2023
      Podcast

      In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.


      Line illustration of a lung on a cornflower blue background

      Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC

      Kristi Rosa
      June 15th 2025
      Article

      Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.


      Image of a person holding a model of the female reproductive system

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Gina Mauro
      June 13th 2025
      Article

      Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.

      Related Content

      Graphic of kidneys

      Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC

      Kyle Doherty
      July 1st 2025
      Article

      ALLO-316 showed significant activity and safety in patients with metastatic CD70-positive clear cell renal cell carcinoma.


      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Fischer
      April 3rd 2023
      Podcast

      Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.


      Image of icons representing different organs in a circle with the female reproductive system in the middle under a magnifying glass

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      Chris Ryan
      June 23rd 2025
      Article

      The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.


      The Vitals

      Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

      Lindsay Fischer
      March 1st 2023
      Podcast

      In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.


      Line illustration of a lung on a cornflower blue background

      Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC

      Kristi Rosa
      June 15th 2025
      Article

      Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.


      Image of a person holding a model of the female reproductive system

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Gina Mauro
      June 13th 2025
      Article

      Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.

      Latest Conference Coverage

      Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC

      No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.